ImmuCell Corp (ICCC) - Financial and Strategic SWOT Analysis Review

November 2021 | 46 pages | ID: I5B25FED6EEEN
GlobalData

Abstracts

ImmuCell Corp (ICCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ImmuCell Corp (Immucell) is an animal health biotechnology company. It develops, manufactures and markets products that improve animal health and productivity in the beef cattle and dairy industry. The company’s flagship product includes First Defense, a bovine coronavirus-escherichia coli antibody and its product line extension, First Defense Tri-Shield. First Defense is the United States Department of Agriculture (USDA)

licensed antibodies which provide Immediate Immunity to the calves against corona virus and E.coli K99. It also offers California Mastitis Test Kit for early detection of mastitis. Immucell is developing Re - Tain, an intramammary infusion product for the treatment of subclinical mastitis in lactating dairy cows. The company sells its products through distributors and dairy producers. ImmuCell is headquartered in Portland, Maine, the US.

ImmuCell Corp Key Recent Developments

Nov 15,2021: ImmuCell Announces Unaudited Financial Results for the Third Quarter Ended September 30, 2021
Oct 06,2021: ImmuCell Announces Record Preliminary, Unaudited Sales Results for Third Quarter of 2021
Sep 14,2021: Raffael Lichdi, DVM Joins ImmuCell’s Sales & Marketing Team
Aug 05,2021: ImmuCell to Announce Unaudited Financial Results for the Second Quarter Ended June 30, 2021
Jul 07,2021: ImmuCell Announces Strong Preliminary, Unaudited Sales Results for Second Quarter of 2021

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

ImmuCell Corp - Key Facts
ImmuCell Corp - Key Employees
ImmuCell Corp - Key Employee Biographies
ImmuCell Corp - Major Products and Services
ImmuCell Corp - History
ImmuCell Corp - Company Statement
ImmuCell Corp - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Company Overview
ImmuCell Corp - Business Description
Product Category: First Defense Product Line
Performance
Product Category: Other
Performance
Product Category: Other Animal Health
Performance
Geographical Segment: Other
Performance
Geographical Segment: United States
Performance
ImmuCell Corp - SWOT Analysis
SWOT Analysis - Overview
ImmuCell Corp - Strengths
ImmuCell Corp - Weaknesses
ImmuCell Corp - Opportunities
ImmuCell Corp - Threats
ImmuCell Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
ImmuCell Corp, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Nov 15, 2021: ImmuCell Announces Unaudited Financial Results for the Third Quarter Ended September 30, 2021
Oct 06, 2021: ImmuCell Announces Record Preliminary, Unaudited Sales Results for Third Quarter of 2021
Sep 14, 2021: Raffael Lichdi, DVM Joins ImmuCell’s Sales & Marketing Team
Aug 05, 2021: ImmuCell to Announce Unaudited Financial Results for the Second Quarter Ended June 30, 2021
Jul 07, 2021: ImmuCell Announces Strong Preliminary, Unaudited Sales Results for Second Quarter of 2021
Jun 30, 2021: ImmuCell Announces Unaudited Financial Results for the Second Quarter Ended June 30, 2021
May 19, 2021: ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
May 06, 2021: ImmuCell to Announce Unaudited Financial Results for the First Quarter Ended March 31, 2021
Apr 14, 2021: ImmuCell Closes $4,250,000 Equity Financing
Apr 07, 2021: ImmuCell Announces Preliminary, Unaudited Sales Results for First Quarter of 2021

SECTION 5 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

ImmuCell Corp, Key Facts
ImmuCell Corp, Key Employees
ImmuCell Corp, Key Employee Biographies
ImmuCell Corp, Major Products and Services
ImmuCell Corp, History
ImmuCell Corp, Key Competitors
ImmuCell Corp, Ratios based on current share price
ImmuCell Corp, Annual Ratios
ImmuCell Corp, Annual Ratios (Cont...1)
ImmuCell Corp, Annual Ratios (Cont...2)
ImmuCell Corp, Interim Ratios
ImmuCell Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

ImmuCell Corp, Performance Chart (2016 - 2020)
ImmuCell Corp, Ratio Charts